<DOC>
	<DOCNO>NCT02209298</DOCNO>
	<brief_summary>This observational study intend collect real-world ( post-approval use ) data regard clinical utility performance Medtronic CoreValve® System Transcatheter Aortic Valve Implantation ( TAVI ) .</brief_summary>
	<brief_title>CoreValve VIVA Study Evaluation Clinical Outcomes CoreValve Degenerative Surgical Aortic Bioprosthesis .</brief_title>
	<detailed_description>To collect real-world ( post-approval use ) data regard clinical utility performance Medtronic CoreValve® System TAVI patient fail surgical aortic bioprosthesis high risk redo surgery .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Patient &gt; 18 year old Patient symptomatic degeneration aortic bioprosthesis Acceptable candidate elective treatment Medtronic CoreValveTM System ( accord recent version Medtronic CoreValveTM Instructions For Use ) conformity local regulatory reimbursement context Logistical Euroscore &gt; 20 % STS &gt; 10 % presence comorbidities responsible contraindication ( ) redo surgery assess least one cardiac surgeon patient heart team assess redo surgery high risk The patient legal representative inform nature procedure study consent participate , authorize collection release his/her medical information sign consent form ( `` Patient Informed Consent Form '' ) The patient willing able comply requirement study , include 24 month followup Patient receive CoreValveTM device degenerate surgical bioprosthesis Patients antiplatelet and/or anticoagulant therapy contraindicate Patient heart team considers risk TAVI high particular attention risk coronary occlusion Patient prior endocarditis fail bioprosthesis Patient medical illness associate limited life expectancy ( i.e. , less 1 year ) Patient LVEF &lt; 20 % , cardiogenic shock , hemodynamic compromise require pressor inotropes mechanical support device Patient severe mitral disease associate severe pulmonary hypertension Acute coronary syndrome le 7 day intervention Currently participate another investigational drug device study . Patient significant paravalvular regurgitation Patient internal diameter prosthesis equal 17 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>